Larry Hahn, DO
Adult Medicine · Trevose, PANPI 1619911609
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,816 of the $8,155 with a category attached, or 71.3%. 33 manufacturers reported payments, led by Johnson & Johnson at 33.0% of the total. Reporting peaked in 2019 at $3,209 and has fallen 70.3% since, to $953 in 2025. Among adult medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- AbbVie$640
- Pfizer$627
- Novo Nordisk$576
- AstraZeneca$486
- GSK$357
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$1,50018%
- Travel & lodging$79910%
- Food & beverage$5,81671%
- Education$410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 19 | $2,689 |
| AbbVie | 43 | $640 |
| Pfizer | 55 | $627 |
| Novo Nordisk | 31 | $576 |
| AstraZeneca | 30 | $486 |
| GSK | 19 | $357 |
| Amgen | 20 | $353 |
| Amarin Pharma, Inc. | 15 | $265 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $246 |
| Lilly USA, LLC | 13 | $237 |
| Exact Sciences | 11 | $219 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $202 |
| Merck | 9 | $136 |
| Astellas Pharma US Inc | 8 | $135 |
| Bausch Health US, LLC | 6 | $117 |
| Esperion Therapeutics, Inc. | 6 | $104 |
| Boehringer Ingelheim | 4 | $100 |
| Sumitomo Pharma America, Inc. | 5 | $98 |
| Kowa Pharmaceuticals America, Inc. | 7 | $94 |
| Novartis | 4 | $69 |
| Optos, Inc. | 2 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Abbott | 2 | $42 |
| Azurity Pharmaceuticals, Inc. | 2 | $42 |
| Inspire Medical Systems, Inc. | 2 | $41 |
| Radius Health, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Bayer | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,155 in reported general payments places this provider in the 90th percentile of 52 adult medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $118,170 |
| OzempicSemaglutide | 78 | $95,664 |
| JardianceEmpagliflozin | 57 | $68,752 |
| FarxigaDapagliflozin Propanediol | 46 | $43,926 |
| JanuviaSitagliptin Phosphate | 43 | $42,628 |
| MounjaroTirzepatide | 28 | $32,994 |
| VascepaIcosapent Ethyl | 38 | $23,756 |
| XareltoRivaroxaban | 21 | $17,126 |
| Lurasidone Hcl | 14 | $12,053 |
| Rosuvastatin Calcium | 632 | $11,287 |
| Icosapent Ethyl | 18 | $8,724 |
| InvokanaCanagliflozin | 14 | $8,091 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 26 | $7,977 |
| Atorvastatin Calcium | 575 | $7,071 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $627 | $118,170101 claims |
| Novo NordiskOzempic | $576 | $95,66478 claims |
| Boehringer IngelheimJardiance | $100 | $68,75257 claims |
| AstraZenecaFarxiga, Symbicort | $486 | $50,60567 claims |
| MerckJanuvia | $136 | $42,62843 claims |
| Lilly USA, LLCMounjaro | $237 | $32,99428 claims |
| Johnson & JohnsonXarelto, Invokana | $2,689 | $25,21735 claims |
| GSKArexvy | $357 | $7,97726 claims |
| AbbVieSynthroid | $640 | $3,03148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 52 adult medicine providers in Pennsylvania.
Other adult medicine in Trevose
- Peter HonigPhiladelphia$140K
- Mark WatkinsPhiladelphia$54K
- Emily ScaruzziPhiladelphia$16K
- Harvey SpectorPhiladelphia$15K
- Gina SloboginUpper Chichester$15K
- Gregory GeorgeSharon$7K
- Victoria KorkusPhoenixville$4K
- Jay RobinsonCoalport$3K
- Matthew KulkaLanghorne$2K
- Matthew SophyPort Carbon$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.